{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "SEK", "marketState": "CLOSED", "regularMarketChangePercent": 0.0, "regularMarketPrice": 88.1, "exchange": "CXE", "shortName": "Xbrane Biopharma AB", "longName": "Xbrane Biopharma AB (publ)", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683117119, "earningsTimestamp": 1676624400, "earningsTimestampStart": 1689850740, "earningsTimestampEnd": 1690200000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -6.59, "sharesOutstanding": 0, "bookValue": 15.447, "fiftyDayAverage": 88.1, "fiftyDayAverageChange": 0.0, "fiftyDayAverageChangePercent": 0.0, "twoHundredDayAverage": 88.1, "twoHundredDayAverageChange": 0.0, "twoHundredDayAverageChangePercent": 0.0, "marketCap": 2376523776, "priceToBook": 5.703373, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1683097200000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketDayHigh": 88.1, "regularMarketDayRange": "88.1 - 88.1", "regularMarketDayLow": 88.1, "regularMarketVolume": 33, "regularMarketPreviousClose": 88.1, "bid": 0.0, "fullExchangeName": "Cboe UK", "financialCurrency": "SEK", "regularMarketOpen": 88.1, "averageDailyVolume3Month": 33, "averageDailyVolume10Day": 33, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "88.1 - 88.1", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "fiftyTwoWeekLow": 88.1, "fiftyTwoWeekHigh": 88.1, "symbol": "XBRANS.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Retzius vAeg 8", "city": "Solna", "zip": "171 65", "country": "Sweden", "phone": "46 8 55 90 56 00", "website": "https://www.xbrane.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.", "fullTimeEmployees": 79, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin  \u00c5mark", "age": 42, "title": "Chief Exec. Officer", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 3100000, "fmt": "3.1M", "longFmt": "3,100,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Siavash  Bashiri", "age": 39, "title": "COO, Head of Biosimilars & Deputy CEO", "yearBorn": 1983, "fiscalYear": 2022, "totalPay": {"raw": 1634000, "fmt": "1.63M", "longFmt": "1,634,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Associate Prof. Jan-Willem  De Gier", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Samuel  Wagner Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anette  Lindqvist", "age": 61, "title": "CFO & Head of Investor Relations", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David  Vikstr\u00f6m", "age": 45, "title": "Chief Technology Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Erik  Domines", "age": 58, "title": "Gen. Counsel", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nina  Ivers", "age": 52, "title": "Head of HR", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Dina  Jurman", "age": 40, "title": "Head of Clinical Affairs", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Maria  Edebrink", "age": 53, "title": "Head of Regulatory Affairs & Quality Assurance", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}